Home | Life Sciences Intellectual Property Review
WEB3 days ago · Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move. 27 August 2024 Biopharma firm sues CSPC for allegedly infringing Onivyde patent issued in August | Suit follows complaint in April asserting eight patents against Conjupro ...
Latest News & Features | Life Sciences Intellectual Property Review
WEBSep 3, 2024 · Brown Rudnick expands with new partner duo. Firm adds pair to its Washington DC office | Both bring experience in patent counselling and IP transactions | Expertise in biotech, life sciences, pharmaceutical sectors, consumer products, biomedical, chemical, food science, agriculture, and medical devices. 5 …
Biotechnology | Life Sciences Intellectual Property Review
WEB21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations. 16 May 2024 Puritan Medical argued it had immunity under PREP Act in patent suit | Fed Circ said ...
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Case review: Biogen v Medeva, 20 years on
WEBMar 25, 2015 · Case review: Biogen v Medeva, 20 years on. It may be hard to imagine Napoleon and the Duke of Wellington sitting down to reminisce after the Battle of Waterloo, and it’s perhaps just as hard to imagine warring legal parties doing so after a long and hard-fought battle. But that is what happened in February when the parties involved in the ...
EPO’s new examination guidelines: what you need to know
WEBApr 6, 2021 · A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.
Generics | Life Sciences Intellectual Property Review
WEBThe pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP. 28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions ...
Unified Patent Court | Life Sciences Intellectual Property Review
WEBLSIPR 50 2017: Sean Dennehey—Steering the ship. From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed. All features. 28 November 2023 UPC judge, …
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
Magazine Archive | Life Sciences Intellectual Property Review
WEBMagazine Archive. Click the thumbnails below to view the Life Sciences IP Review magazines. LSIPR Spring/Summer 2022. Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape. LSIPR new recruit Sarah Speight asks ...